In yesterday’s Wall Street session, Vascular Biogenics Ltd. (NASDAQ:VBLT) shares traded at $0.25, up 3.69% from the previous session.
As of this writing, 1 analysts cover Vascular Biogenics Ltd. (NASDAQ:VBLT). The consensus rating among analysts is ‘Hold’. As we calculate the median target price by taking the range between a high of $5.00 and a low of $5.00, we find $5.00. Given the previous closing price of $0.24, this indicates a potential upside of 1983.33 percent. VBLT stock price is now 31.90% away from the 50-day moving average and 55.77% away from the 200-day moving average. The market capitalization of the company currently stands at $18.71M.
Top 5 EV Tech Stocks to Buy for 2023
The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".
Click Here to Download the FREE Report.
Sponsored
There are 1 analysts who have given it a hold rating, whereas 0 have given it a buy rating. Brokers who have rated the stock have averaged $5.00 as their price target over the next twelve months.
A total of 12.87% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in VBLT stock. A new stake in Vascular Biogenics Ltd. shares was purchased by URBAN WEALTH MANAGEMENT, LLC during the first quarter worth $3,000. In total, there are 33 active investors with 17.60% ownership of the company’s stock.
Thursday morning saw Vascular Biogenics Ltd. (NASDAQ: VBLT) opened at $0.2480. During the past 12 months, Vascular Biogenics Ltd. has had a low of $0.10 and a high of $2.20. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 3.50, and a quick ratio of 3.50. The fifty day moving average price for VBLT is $0.1935 and a two-hundred day moving average price translates $0.1627 for the stock.
The latest earnings results from Vascular Biogenics Ltd. (NASDAQ: VBLT) was released for Dec, 2022. According to the Biotechnology Company, earnings per share came in at -$0.12, missing analysts’ expectations of -$0.11 by -0.01. This compares to -$0.13 EPS in the same period last year.
Vascular Biogenics Ltd.(VBLT) Company Profile
Vascular Biogenics Ltd., a biopharmaceutical company, develops therapeutics for the treatment of cancer and immune-inflammatory diseases in Israel and the United States. It develops VB-601 using monocyte targeting technology for various inflammatory indications. The company was formerly known as Medicard Ltd. and changed its name to Vascular Biogenics Ltd. in January 2003. Vascular Biogenics Ltd. was incorporated in 2000 and is headquartered in Modi’in, Israel.
